Remove what drives disease.
Equilibrium Health is building a portfolio of patented technology around one idea: physically remove the root cause of disease from the body.
Identify
Bind
Remove
A removal-based platform for diseases where a harmful substance can be measured and filtered out of the blood or spinal fluid.
At a glance
One idea. Multiple shots at big diseases.
If disease is driven by harmful substances in the body, the simplest treatment may be to remove it entirely.
Methodology
Most Medicine Adds. We Remove.
Dr. Felder's approach asks: what if we removed the disease-causing substance out of the body in its entirety?
Find the target
Identify the harmful proteins or chemicals in the blood or spinal fluid that are causing or worsening the disease.
Build the binder
Create molecules designed to lock onto and capture that specific target.
Remove it
Filter the harmful substance out of the body's fluid and return the cleaner fluid back in.
Consolidated IP
One approach, multiple diseases to target.
Each asset is a different disease. The same core method — find it, bind it, remove it — applies to all of them.
Lead platform
Alzheimer's
Designed to remove the harmful proteins that build up in the brain's fluid and drive Alzheimer's disease.
- Problem
- Alzheimer's costs the U.S. hundreds of billions of dollars every year — and there is still no cure.
- Difference
- Instead of adding more drugs, this removes the proteins believed to cause the damage in the first place.
- Status
- Lab tests show steps 1–4 complete. Target proteins were nearly eliminated from spinal fluid samples.
New patent focus
Multiple sclerosis
Removes the inflammatory signals in blood and spinal fluid that drive MS flare-ups and nerve damage.
- Problem
- MS is caused by the immune system attacking the brain and spine. Flare-ups feed on themselves.
- Difference
- Goes after the root signal driving the attack — not just one cell type at a time.
- Status
- U.S. Patent 12,521,475 granted January 13, 2026.
Brain injury
TBI nasal spray
A nasal spray treatment designed to reduce brain inflammation and nerve damage in the days after a head injury.
- Problem
- Traumatic brain injury (TBI) affects soldiers, athletes, first responders, and older adults. The CDC reports 214,000+ TBI hospitalizations per year in the U.S. — and many more go untreated.
- Difference
- A simple nasal spray — given in the first days after injury — could reduce the brain damage that builds up over time. No surgery. No IV. Easy to use in the field or ER.
- Status
- Mississippi State University pilot study (2023): Treated rats showed brain inflammation markers (GFAP) 25% lower at day 3 and 28% lower at day 6 versus untreated injured rats. Neuron damage markers (NSE) returned to near-normal levels by day 6 in treated rats but stayed 51% elevated in untreated controls. Study by Dr. Russell Carr and Dr. Anna Marie Clay.
Cancer
Cancer immunotherapy
Research using the immune system's own tools to attack cancer — and to remove cancer-linked substances from the body.
- Problem
- Cancer treatment is one of the most expensive areas in medicine. Many therapies come with serious side effects.
- Difference
- Uses antibodies to activate the immune system and filter out substances that help cancer survive.
- Status
- Preclinical research accepted for presentation at AACR and published in the British Journal of Cancer.
LDN+
Addiction, pain, and PTSD
A patented combination drug for addiction, chronic pain, inflammation, and PTSD — using very low doses of two existing medications.
- Problem
- Overdose deaths and chronic pain affect tens of millions of Americans. Current treatments are often addictive or carry heavy side effects.
- Difference
- Low-dose combination may give doctors a safer tool to use alongside other treatments.
- Status
- Addressable U.S. market above $20B per year.
Optionality
Infectious disease
The same removal system can be aimed at viruses, bacteria, or the dangerous immune overreactions they cause.
- Problem
- Fast-moving infections often outpace how quickly new drugs can be developed and approved.
- Difference
- The approach is modular: swap out the target, keep the removal system. Same platform, new disease.
- Status
- Business plan materials outline antibody targeting and blood filtration concepts for infectious disease.
Validation record
Early data shows promising signal.
What has been shown
- In lab tests, Alzheimer's-linked proteins were nearly eliminated from spinal fluid samples.
- In a 2023 Mississippi State University study, rats treated with the nasal spray after a head injury had significantly lower brain damage markers than untreated rats.
- Cancer research was accepted at AACR and published in the British Journal of Cancer.
- Research partnerships with Arizona State, Youngstown State, Mississippi State, and UTEP.
What still needs to be proven
- Safety and effectiveness in larger animals for the brain-disease applications.
- Human safety, proper dosing, and a clear path through FDA approval for each disease.
- Manufacturing processes that can be repeated at scale for clinical use.
- Insurance coverage and payment models for each treatment setting.
Science
The Felder Doctrine Explained
Opportunity math
Billions in untapped market potential.
This is a model, not a guarantee. Adjust the market share and revenue multiple to see what one successful treatment could be worth.
TAM proxy
$0
Annual revenue at selected share
$0
Implied company value
$0
Return on investment*
0x
* Based on a starting valuation of $30M.
1% of a $409B U.S. care-cost proxy.
1% of the $100B+ immunotherapy segment referenced in source materials.
1% of the $20B+ U.S. opportunity cited in source one-pagers.
Illustrative treatment-volume proxy before sports, military, and outpatient expansion.
Investor fit
For investors who want life changing returns and to change lives.
High scientific risk with a clear step-by-step path to validation.
Multiple diseases, one unified platform — each asset is its own opportunity.
Multiple exit paths: licensing, joint ventures, or strategic acquisition.
A chance to build something that extends healthy life and reduces suffering at scale.
Contact
Request Investor Materials
Get in touch to help shape the future of medicine and learn more about the market opportunity.
This website is provided solely for informational purposes and shall not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation regarding any investment product or securities transaction. Nothing on this website constitutes investment, legal, tax, medical, regulatory, or other professional advice, and no information should be relied upon as the basis for any investment decision. Any forward-looking statements, market estimates, projections, timelines, scientific descriptions, or development plans are inherently uncertain and subject to change. Equilibrium Health's technologies are investigational, may require additional research, clinical validation, regulatory review, and approval, and may never be commercialized. Prospective investors should conduct their own independent diligence, consult their own advisors, and review definitive offering materials, if any, before making any decision.